var data={"title":"Sulfasalazine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sulfasalazine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6999?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sulfasalazine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sulfasalazine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=sulfasalazine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sulfasalazine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223903\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Azulfidine;</li>\n      <li>Azulfidine EN-tabs</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223904\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Sulfasalazine;</li>\n      <li>PMS-Sulfasalazine;</li>\n      <li>Salazopyrin;</li>\n      <li>Salazopyrin En-Tabs</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223946\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        5-Aminosalicylic Acid Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223907\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> Oral: Delayed release: Initial: 500 mg once daily or 1 g/day in 2 divided doses; increase weekly to maintenance dose: 2 g/day in 2 divided doses; maximum: 3 g/day (if response to 2 g/day is inadequate after 12 weeks of treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis:</b> Oral: Immediate and delayed release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 3 to 4 g/day in divided doses at &le;8-hour intervals; may initiate therapy with 1 to 2 g/day to reduce GI intolerance. Doses &gt;4 g/day can increase the risk of toxicity. <b>Note:</b> American College of Gastroenterology guideline recommendations: Titrate to 4 to 6 g daily in 4 divided doses (Kornbluth 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: 2 g/day in divided doses at &le;8-hour intervals when endoscopic exam confirms improvement</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosage adjustment: If GI intolerance occurs, reduce dosage by 50% and gradually increase to target dose over several days. If GI intolerance persists, stop therapy for 5 to 7 days and reintroduce at a lower daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ankylosing spondylitis (off-label use)</b>: Oral: Initial: 500 mg once daily; may increase up to 2 to 3 g/day in divided doses; if intolerance occurs, decrease dose by 500 mg each week as needed (Braun 2011; Clegg 1999; Dougados 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease, active mild/moderate, ileocolonic or colonic disease (off-label use):</b> Oral: 3 to 6 g/day in divided doses (Lichtenstein 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriasis (off-label use):</b> Oral: Initial: 500 mg twice daily; Maintenance: doses may be increased to 3 to 4 g/day as tolerated (Menter 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis (off-label use):</b> Oral: Initial: 500 mg once daily; may increase up to 2 to 3 g daily in divided doses (Clegg 1996; Clegg 1999; Gupta 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Desensitization regimen:</i> For patients who may be sensitive to treatment, it is suggested to start with a total dose of 50 to 250 mg daily and double it every 4 to 7 days until the desired therapeutic level is achieved. Discontinue if symptoms of sensitivity occur. Do not attempt in patients with a history of agranulocytosis or those who have had a previous anaphylactoid reaction on sulfasalazine therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223926\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=sulfasalazine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sulfasalazine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Juvenile rheumatoid arthritis:</b> Children &ge;6 years and Adolescents: Oral: Delayed release: Manufacturer's labeling: Initial: <sup>1</sup>/<sub>4</sub> to <sup>1</sup>/<sub>3</sub> of expected maintenance dose; increase weekly to a maintenance dose of 30 to 50 mg/kg/day in 2 divided doses; maximum: 2 g/day. <b>Note:</b> Although an FDA-approved indication, the use of sulfasalazine for treatment of Juvenile Idiopathic Arthritis (JIA) is not recommended (Ringold 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis: </b>Children &ge;6 years and Adolescents: Oral: Immediate and delayed release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 40 to 60 mg/kg/day in 3 to 6 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: 30 mg/kg/day in 4 divided doses when endoscopic exam confirms improvement</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosage adjustment: If GI intolerance occurs, reduce dosage by 50% and gradually increase to target dose over several days. If GI intolerance persists, stop therapy for 5 to 7 days and reintroduce at a lower daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Desensitization regimen:</i> Refer to adult dosing for patients who may be sensitive to treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223908\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223909\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with extreme caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223910\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with extreme caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223882\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azulfidine: 500 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azulfidine EN-tabs: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223868\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223886\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Tablets should be administered in evenly divided doses, preferably after meals. Delayed-release tablets should be swallowed whole.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223885\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Juvenile rheumatoid arthritis:</b> Delayed release: Treatment of pediatric patients with polyarticular-course juvenile rheumatoid arthritis who have responded inadequately to salicylates or other NSAIDs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> Delayed release: Treatment of rheumatoid arthritis in patients who have responded inadequately to salicylates or other NSAIDs. <b>Note:</b> Treatment initiation with a DMARD is recommended in DMARD-naive patients with either early rheumatoid arthritis (RA) (disease duration &lt;6 months) or established RA (disease duration &ge;6 months) (Singh [ACR 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis:</b> Immediate and delayed release: Treatment of mild to moderate ulcerative colitis; adjunctive therapy in severe ulcerative colitis; prolongation of the remission period between acute attacks of ulcerative colitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744907\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Ankylosing spondylitis; Crohn disease; Psoriasis; Psoriatic arthritis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223953\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SulfaSALAzine may be confused with salsalate, sulfADIAZINE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azulfidine may be confused with Augmentin, azaTHIOprine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223875\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (RA 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (RA 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (RA 19%), dyspepsia (RA 13%), anorexia, gastric distress, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Oligospermia (reversible)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pruritus (RA 4%), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain (RA 8%), stomatitis (RA 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Leukopenia (RA 3%), thrombocytopenia (RA 1%), Heinz body anemia, hemolytic anemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Abnormal hepatic function tests (RA 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cyanosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports (includes reactions reported with mesalamine or other sulfonamides): Agranulocytosis, alopecia, anaphylaxis, angioedema, aplastic anemia, arthralgia, ataxia, cauda equina syndrome, cholestasis, cholestatic hepatitis, cholestatic jaundice, conjunctival injection, crystalluria, depression, diarrhea, DRESS syndrome, drowsiness, eosinophilia, exfoliative dermatitis, folate deficiency, fulminant hepatitis, Guillain-Barr&eacute; syndrome, hallucination, hearing loss, hematologic abnormality, hematologic disease (pseudomononucleosis), hematuria, hemolytic-uremic syndrome, hepatic cirrhosis, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani, 2014), hypoglycemia, hypoprothrombinemia, injected sclera, insomnia, interstitial nephritis, interstitial pulmonary disease, jaundice, Kawasaki syndrome (single case report), lupus-like syndrome, megaloblastic anemia, meningitis, methemoglobinemia, myelitis, myelodysplastic syndrome, myocarditis (allergic), nephritis, nephrolithiasis, nephrotic syndrome, neutropenia (congenital), neutropenic enterocolitis, oropharyngeal pain, pallor, pancreatitis, parapsoriasis varioliformis acuta, periarteritis nodosa, pericarditis, periorbital edema, peripheral neuropathy, pleurisy, pneumonia, pneumonitis, proteinuria, pulmonary alveolitis, purpura, renal disease (acute), rhabdomyolysis, seizure, sepsis, serum sickness-like reaction (children with JRA have frequent and severe reaction), skin discoloration, skin photosensitivity, Stevens-Johnson syndrome, thyroid function impairment, tinnitus, toxic epidermal necrolysis, toxic nephrosis, urinary tract infection, urine discoloration, vasculitis, vertigo </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223889\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sulfasalazine, its metabolites, sulfonamides, salicylates, or any component of the formulation; intestinal or urinary obstruction; porphyria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated with other sulfonamide-containing drug classes, the scientific basis of this statement has been challenged. See &quot;Warnings/Precautions&quot; for more detail.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe renal impairment (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>); severe hepatic impairment; use in pediatric patients &lt;2 years of age; patients in whom acute asthmatic attacks, urticaria, rhinitis, or other allergic manifestations are precipitated by acetyl salicylic acid (ASA) or other NSAIDs</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223872\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Fatalities associated with severe reactions, including agranulocytosis, aplastic anemia, and other blood dyscrasias, have occurred; discontinue use at first sign of rash or signs of serious adverse reactions. The presence of clinical signs such as sore throat, fever, pallor, or purpura may be indicative of a serious blood disorder. Use with extreme caution in patients with blood dyscrasias; monitor CBC frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Deaths from irreversible neuromuscular and CNS changes have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe skin reactions (some fatal), including Stevens-Johnson syndrome (SJS), exfoliative dermatitis, and toxic epidermal necrolysis (TEN), have occurred with sulfonamides (including sulfasalazine), most commonly during the first month of treatment; discontinue use at first sign of skin rash, mucosal lesions, or any other sign of dermatologic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fibrosing alveolitis: Deaths from fibrosing alveolitis have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Folate deficiency: May decrease folic acid absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Nausea, vomiting, and abdominal discomfort commonly occur; titration of dose and/or using the enteric coated formulation may decrease GI adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic necrosis: Fatalities associated with hepatic damage have occurred; discontinue use at first sign of jaundice or hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe and life-threatening reactions, including drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, have been reported. Fever or lymphadenopathy may be present prior to rash development. Other severe hypersensitivity reactions may include internal organ involvement, such as hepatitis, nephritis, myocarditis, mononucleosis-like syndrome, hematologic abnormalities (including hematophagic histiocytosis), and/or pneumonitis including eosinophilic infiltration. Discontinue treatment for severe reactions and evaluate promptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Serious infections (some fatal), including sepsis and pneumonia, have been reported. Infections may be associated with agranulocytosis, neutropenia, or myelosuppression. Monitor for signs/symptoms of infection during and after sulfasalazine therapy and promptly evaluate if infection occurs; discontinue therapy for serious infections. Use cautiously in patients with a history of recurring or chronic infections or with underlying conditions or concomitant therapy which may predispose them to infectious complications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oligospermia: In males, oligospermia (rare) and infertility have been reported; usually reverses upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfonamide (&quot;sulfa&quot;) allergy: Traditionally, concerns for cross-reactivity have extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides. A nonantibiotic sulfonamide compound which contains the arylamine structure and therefore may cross-react with antibiotic sulfonamides is sulfasalazine (Zawodniak 2010). T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergies/asthma: Use with caution in patients with severe allergies or bronchial asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; hemolytic anemia may occur (dose related).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with extreme caution in patients with impaired hepatic function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with extreme caution in patients with renal impairment. Maintain adequate hydration to prevent crystalluria and stone formation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Slow acetylators: Patients classified as slow acetylators may be at increased risk for adverse reactions due to a prolonged half-life of sulfapyrazine (metabolite of sulfasalazine).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Delayed release: Use in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of GI intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites (eg, patients experiencing nausea and vomiting with the first few doses of the drug, patients in whom a reduction in dosage does not alleviate the adverse GI effects).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Enteric-coated tablets: Discontinue if tablets are noted to pass without disintegrating.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin/urine discoloration: May cause skin and urine discoloration (orange/yellow).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300096\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223877\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9963&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: 5-Aminosalicylic Acid Derivatives may decrease the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Folic Acid: SulfaSALAzine may decrease the serum concentration of Folic Acid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Heparins (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: SulfaSALAzine may enhance the hepatotoxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylfolate: SulfaSALAzine may decrease the serum concentration of Methylfolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osimertinib: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rolapitant: May increase the serum concentration of BCRP/ABCG2 Substrates. Management: Monitor patients receiving rolapitant for increased exposure to and/or effects of BCRP/ABCG2 substrates.  Use the lowest effective rosuvastatin dose when used in combination with rolapitant.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: 5-Aminosalicylic Acid Derivatives may decrease the metabolism of Thiopurine Analogs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus-Containing Vaccines: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: May increase the serum concentration of BCRP/ABCG2 Substrates.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9751041\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Sulfasalazine and sulfapyridine cross the placenta; a potential for kernicterus in the newborn exists. Agranulocytosis was noted in an infant following maternal use of sulfasalazine during pregnancy. Additionally, cases of neural tube defects have been reported (causation undetermined); sulfasalazine is known to inhibit the absorption and metabolism of folic acid and may diminish the effects of folic acid supplementation. Based on available data, an increase in fetal malformations has not been observed following maternal use of sulfasalazine for the treatment of inflammatory bowel disease or ulcerative colitis. When treatment for inflammatory bowel disease is needed during pregnancy, sulfasalazine may be used, although supplementation with folic acid is recommended (Habal 2012; Mahadevan 2009; Mottet 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223892\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Sulfasalazine is present in breast milk; sulfapyridine concentrations are ~30% to 60% of the maternal serum. Bloody stools or diarrhea have been reported in breastfeeding infants. Although sulfapyridine has poor bilirubin-displacing ability, exposure may cause kernicterus in the newborn. The manufacturer recommends that caution be exercised when administering sulfasalazine to breastfeeding women. Other sources consider use of sulfasalazine to be safe while breastfeeding; monitoring of the infant is recommended (Habal 2012; Mahadevan 2009; Mottet 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223893\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Sulfasalazine impairs folate absorption. Adequate fluid intake is required to prevent crystalluria and stone formation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9751223\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manufacturer's labeling: CBC with differential and liver function tests (prior to therapy, then every other week for first 3 months of therapy, followed by every month for the second 3 months, then once every 3 months thereafter or as clinically indicated); periodic urinalysis and renal/liver function tests; stool frequency; signs of infection, dermatologic toxicity, or hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate recommendations: Rheumatoid arthritis: Complete blood count, serum creatinine, and LFTs: Baseline and every 2 to 4 weeks for 3 months after initiation or following dose increases, then every 8 to 12 weeks during 3 to 6 months of treatment, followed by every 12 weeks beyond 6 months of treatment; monitor more frequently if clinically indicated (Singh [ACR 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15896591\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Sulfapyridine concentrations &gt;50 mcg/mL are associated with increased adverse events.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223871\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF); action appears topical rather than systemic</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223888\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Rheumatoid arthritis: &gt;4 weeks; Ulcerative colitis: &gt;3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Sulfasalazine: &lt;15% as parent drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Sulfasalazine: &gt;99% to albumin; Sulfapyridine: ~70% to albumin; Acetylsulfapyridine (AcSP): ~90% to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Sulfasalazine: 7.5 &plusmn; 1.6 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Via colonic intestinal flora to sulfapyridine and 5-aminosalicylic acid (5-ASA). Following absorption, sulfapyridine undergoes acetylation to form AcSP and ring hydroxylation while 5-ASA undergoes N-acetylation (non-acetylation phenotype dependent process); rate of metabolism via acetylation dependent on acetylation phenotype</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Sulfasalazine: &lt;15%; Sulfapyridine: ~60%; 5-aminosalicylic acid: ~10% to 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Sulfasalazine: 7.6 &plusmn; 3.4 hours (prolonged in elderly patients); Sulfapyridine: 14.8 hours (slow acetylators) and 10.4 hours (fast acetylators)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Sulfasalazine: 3 to 12 hours (mean: 6 hours); Sulfapyridine and 5-aminosalicylic acid (5-ASA): ~10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (as unchanged drug, conjugates, and acetylated metabolites); feces (small amounts)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223891\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Azulfidine EN-tabs Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $236.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (SulfaSALAzine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $43.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Azulfidine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $181.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (SulfaSALAzine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $24.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223894\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Azulfidina (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Azulfidine (CL, DE, VE);</li>\n      <li>Azulfidine EN-tabs (AR);</li>\n      <li>Azulfidine-EN (CL);</li>\n      <li>Azulfin (BR);</li>\n      <li>Bomecon (TW);</li>\n      <li>Colo-Pleon (DE);</li>\n      <li>Disalazin (PE);</li>\n      <li>Falazine (EC);</li>\n      <li>Gastropyrin (FI);</li>\n      <li>Lazafin (ID);</li>\n      <li>Lazo (LK);</li>\n      <li>Pyralin EN (AU);</li>\n      <li>Rosulfant (CO);</li>\n      <li>SAAZ (IN);</li>\n      <li>Salazex (BD);</li>\n      <li>Salazine (TH, TW);</li>\n      <li>Salazo (BD);</li>\n      <li>Salazodin (UY);</li>\n      <li>Salazopirina (PT);</li>\n      <li>Salazopiryn EN (UA);</li>\n      <li>Salazopyrin (AE, AT, AU, BH, CH, CY, DK, EG, FI, GB, HN, HU, IE, IL, IQ, IR, IS, IT, JO, KW, LB, LV, LY, NZ, OM, PK, PL, QA, SA, SE, SY, TR, YE, ZA, ZW);</li>\n      <li>Salazopyrin EN (HR, MT, RO);</li>\n      <li>Salazopyrin Entabs (AE, BH, CY, DK, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Salazopyrin-EN (AU, BG, CH, CO, CZ, EE, FI, GB, HK, IL, IT, MY, NO, NZ, SE, TH, TW, ZA);</li>\n      <li>Salazopyrina (ES);</li>\n      <li>Salazopyrine (BE, FR, LU, NL, VN);</li>\n      <li>Salazopyrine EC (BE);</li>\n      <li>Salivon (ID);</li>\n      <li>Salopyr (FI);</li>\n      <li>Salopyrine (GR);</li>\n      <li>Saridine-E (HK, TH);</li>\n      <li>Sazo (LK);</li>\n      <li>Sulcolon (ID);</li>\n      <li>Sulfasalazin (HR);</li>\n      <li>Sulfitis (ID);</li>\n      <li>Sulsa 500 (TH);</li>\n      <li>Sulzin (BD);</li>\n      <li>Zopyrin (HK, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ardizzone S, Porro GB. A Practical Guide to the Management of Distal Ulcerative Colitis. <i>Drugs. </i>1998;55(4):519-542.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/9561342/pubmed\" target=\"_blank\" id=\"9561342\">9561342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azulfidine (sulfasalazine) [prescribing information]. Kalamazoo, MI: Pharmacia &amp; Upjohn; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azulfidine EN-tabs (sulfasalazine) [prescribing information]. Kalamazoo, MI: Pharmacia &amp; Upjohn; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/15303450/pubmed\" target=\"_blank\" id=\"15303450\">15303450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21630245\"></a>Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. <i>Arthritis Rheum</i>. 2011;63(6):1543-1551.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/21630245/pubmed\" target=\"_blank\" id=\"21630245\">21630245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10555027\"></a>Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. <i>Arthritis Rheum</i>. 1999;42(11):2325-2329.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/10555027/pubmed\" target=\"_blank\" id=\"10555027\">10555027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8961906\"></a>Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs cooperative study. <i>Arthritis Rheum</i>. 1996;39(12):2013-2020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/8961906/pubmed\" target=\"_blank\" id=\"8961906\">8961906</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26749174\"></a>Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. <i>Arthritis Rheumatol</i>. 2016;68(5):1060-1071.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/26749174/pubmed\" target=\"_blank\" id=\"26749174\">26749174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7748217\"></a>Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. <i>Arthritis Rheum</i>. 1995;38(5):618-627.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/7748217/pubmed\" target=\"_blank\" id=\"7748217\">7748217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giannini EH, Cawkwell GD. Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. <i>Pediatr Clin North Am.</i> 1995;42(5):1099-1125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/7567188/pubmed\" target=\"_blank\" id=\"7567188\">7567188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8587078\"></a>Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. <i>J Rheumatol</i>. 1995;22(5):894-898.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/8587078/pubmed\" target=\"_blank\" id=\"8587078\">8587078</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haas RM, Li P, and Chu JW, &ldquo;Glucose-Lowering Effects of Sulfasalazine in Type 2 Diabetes,&rdquo; <i>Diabetes Care</i>, 2005, 28(9):2238-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/16123497/pubmed\" target=\"_blank\" id=\"16123497\">16123497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habal FM, Huang VW. Review article: A decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. <i>Aliment Pharmacol Ther</i>. 2012;35(5):501-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/22221203/pubmed\" target=\"_blank\" id=\"22221203\">22221203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haines JD, Jr, &ldquo;Hepatotoxicity After Treatment With Sulfasalazine,&rdquo; <i>Postgrad Med</i>, 1986, 79(6):193-4, 197-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/2871549/pubmed\" target=\"_blank\" id=\"2871549\">2871549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jick H, Myers MW, and Dean AD, &ldquo;The Risk of Sulfasalazine- and Mesalazine-Associated Blood Disorders,&rdquo; <i>Pharmacotherapy</i>, 1995, 15(2):176-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/7624265/pubmed\" target=\"_blank\" id=\"7624265\">7624265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/15644481/pubmed\" target=\"_blank\" id=\"15644481\">15644481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jullien D, Wokenstein P, Roupie E, et al, &ldquo;Toxic Epidermal Necrolysis After Sulfasalazine Treatment of Mild Psoriatic Arthritis: Warning on the Use of Sulfasalazine for a New Indication,&rdquo; <i>Arthritis Rheum</i>, 1995, 38(4):573.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/7718014/pubmed\" target=\"_blank\" id=\"7718014\">7718014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo; <i>Am J Gastroenterol</i>, 2010, 105(3):501-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/20068560/pubmed\" target=\"_blank\" id=\"20068560\">20068560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo; <i>Am J Gastroenterol</i>, 2009, 104(2):465-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/19174807/pubmed\" target=\"_blank\" id=\"19174807\">19174807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U. Pregnancy and inflammatory bowel disease. <i>Gastroenterol Clin North Am</i>. 2009;38(4):629-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/19913206/pubmed\" target=\"_blank\" id=\"19913206\">19913206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. <i>J Am Acad Dermatol</i>.2009 Sep;61(3):451-85. doi: 10.1016/j.jaad.2009.03.027. Epub 2009 Jun 3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/19493586/pubmed\" target=\"_blank\" id=\"19493586\">19493586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mottet C, Juillerat P, Pittet V, et al. Pregnancy and breastfeeding in patients with Crohn's disease. <i>Digestion</i>. 2007;76(2):149-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/18239407/pubmed\" target=\"_blank\" id=\"18239407\">18239407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Dell JR, &ldquo;Triple Therapy With Methotrexate, Sulfasalazine, and Hydroxychloroquine in Patients With Rheumatoid Arthritis,&rdquo; <i>Rheum Dis Clin North Am</i>, 1998, 24(3):465-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/9710881/pubmed\" target=\"_blank\" id=\"9710881\">9710881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ringold S, Weiss PF, Beukelman T, et al; American Collge of Rheumatology. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Rheum</i>. 2013;65(10):2499-2512. doi: 10.1002/art.38092.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/24092554/pubmed\" target=\"_blank\" id=\"24092554\">24092554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salazopyrin (sulfasalazine) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Rheumatol</i>. 2016;68(1):1-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/26545940/pubmed\" target=\"_blank\" id=\"26545940\">26545940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/15242722/pubmed\" target=\"_blank\" id=\"15242722\">15242722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/15373844/pubmed\" target=\"_blank\" id=\"15373844\">15373844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Rossum MA, Fiselier TJ, Franssen MJ, et al, &ldquo;Sulfasalazine in the Treatment of Juvenile Chronic Arthritis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Dutch Juvenile Chronic Arthritis Study Group,&rdquo; <i>Arthritis Rheum</i>, 1998, 41(5):808-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/9588731/pubmed\" target=\"_blank\" id=\"9588731\">9588731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veale DJ, Ho M, and Morley KD, &ldquo;Sulfasalazine-Induced Lupus in Psoriatic Arthritis,&rdquo; <i>Br J Rheumatol</i>, 1995, 34(4):383-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/7788157/pubmed\" target=\"_blank\" id=\"7788157\">7788157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26401991\"></a>Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. <i>Arthritis Rheumatol</i>. 2016;68(2):282-298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/26401991/pubmed\" target=\"_blank\" id=\"26401991\">26401991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. <i>Int Arch Allergy Immunol</i>. 2010;153(2):152-156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfasalazine-drug-information/abstract-text/20413982/pubmed\" target=\"_blank\" id=\"20413982\">20413982</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9963 Version 161.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F223903\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F223904\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F223946\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F223907\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F223926\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F223908\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F223909\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F223910\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F223882\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F223868\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F223886\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F223885\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744907\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F223953\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F223875\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F223889\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F223872\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300096\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F223877\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9751041\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F223892\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F223893\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9751223\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F15896591\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F223871\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F223888\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F223891\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F223894\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9963|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sulfasalazine-patient-drug-information\" class=\"drug drug_patient\">Sulfasalazine: Patient drug information</a></li><li><a href=\"topic.htm?path=sulfasalazine-pediatric-drug-information\" class=\"drug drug_pediatric\">Sulfasalazine: Pediatric drug information</a></li></ul></div></div>","javascript":null}